Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UCKGX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADCT-701
|
|||||
| Synonyms |
ADCT 701; ADCT-701; ADCT701; Humanized anti-DLK1 antibody ADC; LIV-1205 ADC
Click to Show/Hide
|
|||||
| Organization |
Cancer Research Technology Ltd.; ADC Therapeutics SA
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
HuBa-1-3D
|
Antibody Info | ||||
| Antigen Name |
Protein delta homolog 1 (DLK1)
|
Antigen Info | ||||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
BCN-HydraSpace-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
| Combination Type |
uzoptirine
|
|||||
